Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suraxavir marboxil in high-risk influenza
NCT06573008Phase 3Recruiting
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Start
- Nov 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in influenza comparing GP681 40mg with Placebo (2 arms). Primary endpoint: Time to alleviation of influenza symptoms at Day 15. Started Nov 2024; status: recruiting.
02
Drugs
suraxavir marboxil
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06573008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06573008.